Hey Mr. Moreau here's an idea!If your IPF/Chronic Cough study is only 20 people, which is a crazy small number, why not just do a Chronic Cough ONLY study for the same number of 20 people somewhere other than Australia and New Zealand? It seems like you have everything bogged down for a tiny trial that could start and end elsewhere in a matter of months. Look at Bellus Health andnd it's 106 clinical trial locations. How long would it take Algernon to recruit only 20 people with that many locations? It just seems like the urgency or need to get to a data readout in a timely manner is not the most important objective of the company. When do you throw all caution to the wind and just get stuff done? The terrain is looking treacherous if you plan to wait for full enrollment in Australia and new Zealand. It was a bad move that doesn't need to continue getting worse if you just pivot and get after it. Where's the fight? Where's the urgency? I just don't see it with the team in place at Algernon.